Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 100

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 6
Chunk 100
---
Item 6.
Directors, Senior Management and Employees

(Start of the Remuneration Report forAustralian Disclosure Requirements)

The Radiopharm Theranostics Limited Board of Directors (“the
Board”) presents the 2024/2025 Remuneration Report, which has been prepared in accordance with the relevant Corporations Act 2001
(“ Corporations Act”) and accounting standards requirements. The remuneration report sets out remuneration information for
our company’s key management personnel (“ KMP”) as defined in the International Accounting Standards 24 ‘ Related
Party Disclosures’ and the Australian Corporations Act 2001 for the financial year ended June 30, 2025. The remuneration report
has been audited as required by s308 (3C) of the Corporations Act.

A. Directors and Senior Management

The following table sets forth
our directors and senior management. There are no family relationships among any of the members of our board of directors and our senior
management.

  Name                   Position                                                           
  Riccardo Canevari      Chief Executive Officer and Managing Director                      
  Paul Hopper            Executive Chairman                                                 
  Dimitris Voliotis      Chief Medical Officer                                              
  Hester Larkin          Non-Executive Director                                             
  Dr. Leila Alland       Non-Executive Director                                             
  Ian Turner             Non-Executive Director                                             
  Phillip Hains          Executive Director, Chief Financial Officer and Company Secretary  
  Noel Donnelly          Non-Executive Director                                             

Riccardo Canevari. Riccardo
Canevari has been our Chief Executive Officer and Managing Director since September 2021. Mr. Canevari was previously Chief Commercial
Officer of Novartis company, Advanced Accelerator Applications, from April 2020 to September 2021, one of the leading radiopharmaceutical
and nuclear medicine companies globally. He was responsible for commercial strategy and country organizations in approximately 20 countries
across North America, Europe and Asia. Prior to that, he was Senior Vice President and Global Head of the Breast Cancer Franchise for
Novartis Oncology from 2017, where he oversaw the launch of major breast cancer products. Mr. Canevari has also held various management
roles with Novartis Pharma and Ethicon/Johnson & Johnson.

Paul Hopper. Paul Hopper
is founder and Executive Chairman since February 2021. Mr. Hopper is also currently Executive Chairman at Im